Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lilly

Status and phase: Enrolling; Phase 2

Conditions: B-cell Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell

Treatments: Drug: Pirtobrutinib

Study type: Interventional

Funder types: Industry

Identifiers

NCT07162181

27295

J2N-MC-JZNY (Other Identifier)

2024-517760-29-00 (EU Trial (CTIS) Number)

J2N-MC-JZNJ (Other Identifier)

J2N-MC-JZ02 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Enrollment: 13 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Currently enrolled and active in the originator study, JZNJ. A participant is considered active in the study if they are receiving study intervention
• Agree to comply with contraception requirements. Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies

Exclusion criteria

• Are pregnant, or intend to become pregnant during the study, or within 30 days of last dose of study treatment or to breastfeed during the study or within 1 week of the last dose of study treatment

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

13 participants in 1 patient group

Pirtobrutinib

Experimental group

Description:

Pirtobrutinib administered orally.

Treatment:

Drug: Pirtobrutinib